Home
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

Today’s Highlights January 7, 2026

Rapport Therapeutics in the NEWS
Today, January 07, 2026, Rapport Therapeutics, Inc. (RAPP) announced plans to initiate its Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio with a new program in PGTCS.

Additionally, the Company announced progress across its pipeline, including . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
January 7, 2026

Other Articles